To the Editor I read with great interest the excellent article by Adamson and Dusetzina1 published in the January 2017 issue of JAMA Dermatology.1 The authors note that 55% of surgically treated nonmelanoma skin cancers were treated with Mohs micrographic surgery (MMS), while excisions and electrodessication and curettage accounted for 16.2% and 28.8% of procedures, respectively. However, the authors’ suggestions that these numbers are inconsistent with the Appropriate Use Criteria (AUC) for MMS,2 and their implication that these data suggest MMS overuse, merit additional context and comment.
Kantor J. Mohs Micrographic Surgery Use in the United States Based on Medicare Data. JAMA Dermatol. 2017;153(8):834–835. doi:10.1001/jamadermatol.2017.0732
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: